Clinical trials: Sintilimab, completed
Classical Hodgkin Lymphoma
Interim PET/CT-adapted Use of PD-1 Inhibitor Combined With De-escalated Chemotherapy-AVD in Classic Hodgkin Lymphoma
This study enrolls newly diagnosed unfavorable stage II /stage III-IV classical Hodgkin lymphoma patients. All participants receive 2 cycles ABVD induction chemotherapy, then stratified by interim PET-CT Deauville score for…
- Trial name
- NCT07720011
- Testing
- ABVD chemotherapy, Sintilimab and AVD
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Peking University People's Hospital
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, Early Stage
Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma
This study aims to investigate the treatment of previously untreated stage I-II Extranodal NK/T Cell Lymphoma with sintilimab, peg-aspargase and anlotinib, "sandwich" with radiotherapy.
- Conditions
- Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, Early Stage, Anlotinib, Peg-aspargase
- Trial name
- NCT03936452
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer, Immunotherapy
Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)
This study is designed to evaluate the efficacy and safety of the combination of Anlotinib and Sintilimab in advanced colorectal cancer as first-line treatment.
- Conditions
- Colorectal Cancer, Immunotherapy, Anlotinib, Sintilimab
- Trial name
- NCT04271813
- Testing
- Anlotinib plus Sintilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Changzheng Hospital
Advanced or Metastatic NSCLC
A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients
this is a phase I study comparing PK similarity of sintilimab by different production process (approved versus M1b) in Chinese advanced or metastatic NSCLC patients who have failed or been intolerant to at least one prior line of…
- Trial name
- NCT04177290
- Testing
- Sintilimab (M1b), Sintilimab (approved)
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Non-small Cell Lung Cancer
Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC
This study aims to explore time-of-day of administration of immunochemotherapy on the efficacy for treatment naive advanced non-small cell lung cancer.
- Trial name
- LungTIME-C01 (NCT05549037)
- Testing
- Pembrolizumab, Sintilimab
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Hunan Province Tumor Hospital
NSCLC (Non-small-cell Lung Cancer)
IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)
This is an open label, multicenter, phase Ib study evaluating IBI310 (anti-CTLA-4) in combination with Sintilimab in patients with advanced, recurrent or metastatic non-small-cell lung cancer (NSCLC)
- Trial name
- NCT05118334
- Testing
- Sintilimab, IBI310
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Advanced Malignancies
A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors
This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of IBI939 in subjects with advanced malignancies
- Trial name
- NCT04353830
- Testing
- IBI939, IBI939+ Sintilimab
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Hepatocellular Carcinoma Non-resectable
TACE Combined With Lenvatinib and Sintilimab for Advanced HCC
This study will evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and sintilimab in patients with unresectable advanced hepatocellullar carcinoma (HCC).
- Trial name
- NCT04599790
- Testing
- TACE combined with lenvatinib and sintilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma Non-resectable
TACE Combined With Sorafenib and Tislelizumab for Advanced HCC
This study will evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with sorafenib and tislelizumab in patients with advanced hepatocellullar carcinoma (HCC).
- Trial name
- NCT04599777
- Testing
- TACE combined with sorafenib and tislelizumab
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Esophageal Squamous Cell Carcinoma
The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer
Esophageal cancer is a kind of disease with high incidence and mortality. Definitive concurrent chemoradiotherapy is an important treatment for locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT04212598
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Wuhan University
Esophageal Squamous Cell Carcinoma
Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC
The purpose of this study is to observe and evaluate the efficacy and safety of A sintilimab plus chemotherapy followed by definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT03985046
- Testing
- Sintilimab plus Chemotherapy
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Fudan University
Esophageal Squamous Cell Carcinoma
Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients
An open-label, non-randomized, phase II study to assess the safety and efficacy of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in Borderline Resectable Esophageal Squamous Cell Carcinoma patients
- Trial name
- NCT04548440
- Testing
- Sintilimab, Nab paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-Sen University Cancer Center
Hepatocellular Carcinoma
TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC
The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with PD-1/PD-L1 Inhibitors and molecular target therapies in patients with Intermediate-stage…
- Trial name
- CHANCE2202 (NCT05332496)
- Testing
- PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE
- Where
- 2 sites in China
- Volunteers
- 941 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma
TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC
The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and molecular target therapies in patients with advanced-stage…
- Trial name
- CHANCE2201 (NCT05332821)
- Testing
- PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE
- Where
- 2 sites in China
- Volunteers
- 1,244 people
- Sponsor
- Zhongda Hospital
Metastatic Colorectal Adenocarcinoma
Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC
Fruquintinib with PD-1 inhibitors (FP) and TAS-102 with bevacizumab (TB) are two common therapies for patients with previous-treated metastatic colorectal cancer (mCRC).
- Trial name
- NCT06031376
- Testing
- Fruquintinib, PD-1 inhibitors, Trifluridine/Tipiracil
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Hunan Cancer Hospital
Sintilimab and Anlotinib in Combination With Chemotherapy
Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer
The study focused on patients with T2-4NxM0 resectable esophageal carcinoma. Neoadjuvant treatment involved administering anlotinib (10 mg orally, once a day, 2 weeks on and 1 week off) for anti-angiogenesis and sintilimab (200…
- Trial name
- NCT06015035
- Testing
- Sintilimab and anlotinib in combination with chemotherapy
- Where
- 2 sites in China
- Volunteers
- 17 people
- Sponsor
- Tang-Du Hospital
Advanced Hepatocellular Carcinoma
Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma
This is a Phase Ib study to evaluate the safety, tolerability and efficacy of Sintilimab combined with IBI305 in patients with advanced hepatocellular carcinoma in China.
- Trial name
- NCT04072679
- Testing
- Sintilimab+IBI305
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Chinese Academy of Medical Sciences
Gastric Cancer
Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer
The purpose of this study is to estimate overall survival of Sintilimab+ oxaliplatin + capecitabine and placebo+ oxaliplatin + capecitabine, as first-line treatment of patients with advanced gastric or gastroesophageal junction…
- Trial name
- NCT03745170
- Testing
- Sintilimab, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 650 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Advanced Hepatocellular Carcinoma
Efficacy and Safety of IBI310 Combined with Sintilimab in Patients with Advanced Hepatocellular Carcinoma
An open-label, single-arm, Ib study of the efficacy and safety of IBI310 combined with sintilimab in patients with advanced hepatocellular carcinoma
- Trial name
- NCT04401813
- Testing
- IBI308 200mg
- Where
- China
- Volunteers
- 97 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Solid Tumor, NSCLC
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
This is a multicenter, open-label, dose-escalation and efficacy/safety Phase I/II study to assess RP2D, safety, tolerability and anti-tumor activity of Sintilimab + afuresertib + nab-paclitaxel or docetaxel administered as a…
- Conditions
- Solid Tumor, NSCLC, Cervical Cancer, Endometrial Cancer
- Trial name
- NCT05383482
- Testing
- Afuresertib, Nab paclitaxel, Docetaxel
- Where
- 5 sites in China
- Volunteers
- 22 people
- Sponsor
- Laekna Limited